Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides

J. A. Walder, B. T. Hyman, Michael (Mike) Heller, R. Y. Shishido, I. M. Klotz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The antiprostaglandin action of aspirin due to the acetylation of the enzyme prostaglandin synthetase is manifested by inhibition of the so-called release reaction and consequent abolition of secondary-phase aggregation. The maleic anhydrides, a series of reversible acylating agents, have now been shown to produce the aspirin-type defect in platelet aggregation. The antiplatelet effect of aspirin is irreversible. With 2,3-dimethylmaleic anhydride, however, the antiplatelet effect disappeared in approximately 80 min at 25°. Hence the persistence of the lesion when caused by aspirin results from the stability of the acetyl linkage formed in its reaction with prostaglandin synthetase. This suggests that the modification occurs at either a lysine or an NH 2-terminal amino group. That such is the case was confirmed by the observation that 3,4,5,6-tetrahydrophthalic anhydride and 2,3-dimethylmaleic anhydride, both amino-specific acylating agents, were able to effect the aspirin-type lesion. Thus, upon deacylation, prostaglandin synthetase regains its activity and platelet function returns to normal. Accordingly, it may be possible to develop a clinically acceptable, reversible acylating agent with short-acting, aspirin-like effects.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalMolecular pharmacology
Volume13
Issue number3
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Maleic Anhydrides
Acylation
Platelet Aggregation
Aspirin
Prostaglandin-Endoperoxide Synthases
Anhydrides
Acetylation
Lysine
Blood Platelets
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Walder, J. A., Hyman, B. T., Heller, M. M., Shishido, R. Y., & Klotz, I. M. (1977). Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides. Molecular pharmacology, 13(3), 407-414.

Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides. / Walder, J. A.; Hyman, B. T.; Heller, Michael (Mike); Shishido, R. Y.; Klotz, I. M.

In: Molecular pharmacology, Vol. 13, No. 3, 01.12.1977, p. 407-414.

Research output: Contribution to journalArticle

Walder, JA, Hyman, BT, Heller, MM, Shishido, RY & Klotz, IM 1977, 'Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides', Molecular pharmacology, vol. 13, no. 3, pp. 407-414.
Walder, J. A. ; Hyman, B. T. ; Heller, Michael (Mike) ; Shishido, R. Y. ; Klotz, I. M. / Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides. In: Molecular pharmacology. 1977 ; Vol. 13, No. 3. pp. 407-414.
@article{618106e4911f40a9a0241b195ef81402,
title = "Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides",
abstract = "The antiprostaglandin action of aspirin due to the acetylation of the enzyme prostaglandin synthetase is manifested by inhibition of the so-called release reaction and consequent abolition of secondary-phase aggregation. The maleic anhydrides, a series of reversible acylating agents, have now been shown to produce the aspirin-type defect in platelet aggregation. The antiplatelet effect of aspirin is irreversible. With 2,3-dimethylmaleic anhydride, however, the antiplatelet effect disappeared in approximately 80 min at 25°. Hence the persistence of the lesion when caused by aspirin results from the stability of the acetyl linkage formed in its reaction with prostaglandin synthetase. This suggests that the modification occurs at either a lysine or an NH 2-terminal amino group. That such is the case was confirmed by the observation that 3,4,5,6-tetrahydrophthalic anhydride and 2,3-dimethylmaleic anhydride, both amino-specific acylating agents, were able to effect the aspirin-type lesion. Thus, upon deacylation, prostaglandin synthetase regains its activity and platelet function returns to normal. Accordingly, it may be possible to develop a clinically acceptable, reversible acylating agent with short-acting, aspirin-like effects.",
author = "Walder, {J. A.} and Hyman, {B. T.} and Heller, {Michael (Mike)} and Shishido, {R. Y.} and Klotz, {I. M.}",
year = "1977",
month = "12",
day = "1",
language = "English (US)",
volume = "13",
pages = "407--414",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Reversible acylation and inhibition of aggregation of platelets by substituted maleic anhydrides

AU - Walder, J. A.

AU - Hyman, B. T.

AU - Heller, Michael (Mike)

AU - Shishido, R. Y.

AU - Klotz, I. M.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - The antiprostaglandin action of aspirin due to the acetylation of the enzyme prostaglandin synthetase is manifested by inhibition of the so-called release reaction and consequent abolition of secondary-phase aggregation. The maleic anhydrides, a series of reversible acylating agents, have now been shown to produce the aspirin-type defect in platelet aggregation. The antiplatelet effect of aspirin is irreversible. With 2,3-dimethylmaleic anhydride, however, the antiplatelet effect disappeared in approximately 80 min at 25°. Hence the persistence of the lesion when caused by aspirin results from the stability of the acetyl linkage formed in its reaction with prostaglandin synthetase. This suggests that the modification occurs at either a lysine or an NH 2-terminal amino group. That such is the case was confirmed by the observation that 3,4,5,6-tetrahydrophthalic anhydride and 2,3-dimethylmaleic anhydride, both amino-specific acylating agents, were able to effect the aspirin-type lesion. Thus, upon deacylation, prostaglandin synthetase regains its activity and platelet function returns to normal. Accordingly, it may be possible to develop a clinically acceptable, reversible acylating agent with short-acting, aspirin-like effects.

AB - The antiprostaglandin action of aspirin due to the acetylation of the enzyme prostaglandin synthetase is manifested by inhibition of the so-called release reaction and consequent abolition of secondary-phase aggregation. The maleic anhydrides, a series of reversible acylating agents, have now been shown to produce the aspirin-type defect in platelet aggregation. The antiplatelet effect of aspirin is irreversible. With 2,3-dimethylmaleic anhydride, however, the antiplatelet effect disappeared in approximately 80 min at 25°. Hence the persistence of the lesion when caused by aspirin results from the stability of the acetyl linkage formed in its reaction with prostaglandin synthetase. This suggests that the modification occurs at either a lysine or an NH 2-terminal amino group. That such is the case was confirmed by the observation that 3,4,5,6-tetrahydrophthalic anhydride and 2,3-dimethylmaleic anhydride, both amino-specific acylating agents, were able to effect the aspirin-type lesion. Thus, upon deacylation, prostaglandin synthetase regains its activity and platelet function returns to normal. Accordingly, it may be possible to develop a clinically acceptable, reversible acylating agent with short-acting, aspirin-like effects.

UR - http://www.scopus.com/inward/record.url?scp=0017701579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017701579&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 407

EP - 414

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -